Dr. Zheng has 25 years of experience in investment banking and financing industry, focusing on private placement, IPO/SPAC financing, PIPE, Follow-on Financing, ATM and convertible notes financing.

Dr. Zheng currently serves as the Director of Business Development of, and as a broker with, Craft Capital Management LLC in New York, USA. He is also currently an independent director of NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) in San Francisco, USA, and Mars Acquisition Corp. (NASDAQ: MARXU) in New York, USA. Prior to that, Dr. Zheng served as the Director of Business Development and partner of, and as a broker with, Spartan Securities Group, Ltd. in Florida, USA. Dr. Zheng’s experience includes providing innovative financial solutions and consulting services for initial public offering underwriting and investment banking as well as corporate financing solutions with a particular focus on Chinese companies listed overseas. Dr. Zheng previously served as a financial advisor for various Canadian public companies including: P & P Ventures Inc. (TSX-V: PPV.H) where he served as president and a director; Damon Capital Corp (TSX-V: DAM.H) where he served as Chief Financial Officer and a director; and Cantronic Systems Inc. (TSX-V: CTS) where he served as a director and chair of the audit committee. Dr. Zheng received a Ph.D. in physics from Flinders University of South Australia.